Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss drug showdown: which works better?

NCT ID NCT05822830

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 3 trial tested two injectable weight loss drugs, tirzepatide and semaglutide, in 751 adults with obesity or overweight who also had weight-related health problems like high blood pressure. The study lasted about 74 weeks and measured how much weight participants lost. The goal was to see which drug works better for weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide and semaglutide (injectable weight loss drugs)
What this could lead to
If tirzepatide proves more effective than semaglutide, it could offer a better option for significant weight loss in people with obesity or overweight.
What could go wrong
This is a completed phase 3 trial, but results may not apply to everyone. Both drugs can cause side effects like nausea or vomiting, and weight regain is possible after stopping.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

751 people

The number who actually took part.

Started

Apr 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a body mass index (BMI) of ≥30 kilogram per square meter (kg/m²) or ≥27 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease * Have a history of at least 1 unsuccessful dietary effort to lose body weight Exclusion Criteria: * Diabetes mellitus * Change in body weight greater than 5 kg within 3 months prior to starting study * Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity * History of pancreatitis * Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease Motor Activity Obesity obesity disorder Overweight prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma, 73069, United States

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan, 48098, United States

  • Biopharma Informatic, LLC

    Houston, Texas, 77043, United States

  • Cahaba Research

    Birmingham, Alabama, 35242, United States

  • Cahaba Research - Pelham

    Pelham, Alabama, 35124, United States

  • Dallas Diabetes Research Center

    Dallas, Texas, 75230, United States

  • Encompass Clinical Research

    Spring Valley, California, 91978, United States

  • ForCare Clinical Research

    Tampa, Florida, 33613-1244, United States

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50265, United States

  • L-MARC Research Center

    Louisville, Kentucky, 40213, United States

  • Lillestol Research

    Fargo, North Dakota, 58104, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • North Texas Endocrine Center

    Dallas, Texas, 75231, United States

  • Palm Research Center Sunset

    Las Vegas, Nevada, 89148, United States

  • Palm Research Center Tenaya

    Las Vegas, Nevada, 89128, United States

  • PharmQuest

    Greensboro, North Carolina, 27408, United States

  • Pinnacle Clinical Research

    San Antonio, Texas, 78229, United States

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Prime Health and Wellness/SKYCRNG

    Fayette, Mississippi, 39069, United States

  • Puerto Rico Medical Research

    Ponce, 00717, Puerto Rico

  • Rocky Mountain Clinical Research

    Idaho Falls, Idaho, 83404, United States

  • Rophe Adult and Pediatric Medicine/SKYCRNG

    Union City, Georgia, 30291, United States

  • Southern California Dermatology, Inc.

    Santa Ana, California, 92701, United States

  • Southern Endocrinology Associates

    Mesquite, Texas, 75149, United States

  • StudyMetrix Research

    City of Saint Peters, Missouri, 63303, United States

  • The University of Texas Health Science Center at Houston

    Bellaire, Texas, 77401, United States

  • Tribe Clinical Research, LLC

    Greenville, South Carolina, 29607, United States

  • University Clinical Investigators, Inc.

    Tustin, California, 92780, United States

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida, 33009, United States

  • WR-Clinsearch, LLC

    Chattanooga, Tennessee, 37421, United States

  • Weill Cornell Medical College

    New York, New York, 10021, United States

  • Wellness clinical Research Vega Baja

    Vega Baja, 00694, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.